Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001769173 | SCV002003301 | uncertain significance | not provided | 2020-10-14 | criteria provided, single submitter | clinical testing | Canonical splice site variant expected to result in aberrant splicing, although in the absence of functional evidence the actual effect of this sequence change is unknown.; Has not been previously published as pathogenic or benign to our knowledge |
Baylor Genetics | RCV003470887 | SCV004193665 | uncertain significance | Schwannomatosis 2 | 2023-05-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001769173 | SCV004270025 | likely pathogenic | not provided | 2022-11-24 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 1313222). This variant has not been reported in the literature in individuals affected with LZTR1-related conditions. This variant is present in population databases (rs759240190, gnomAD 0.03%). This sequence change affects an acceptor splice site in intron 11 of the LZTR1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in LZTR1 are known to be pathogenic (PMID: 24362817, 25335493, 25480913, 25795793, 29469822, 30368668, 30442762, 30442766, 30481304, 30859559). |